An Open-Label, Dose Titration Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046, A Sustained-Release Analogue of Vasoactive Intestinal Peptide, In Adult Subjects With Pulmonary Arterial Hypertension
Phase of Trial: Phase I
Latest Information Update: 08 Apr 2018
At a glance
- Drugs PB 1046 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors PhaseBio Pharmaceuticals
- 27 Feb 2018 Planned End Date changed from 28 Feb 2018 to 1 Sep 2018.
- 27 Feb 2018 Planned primary completion date changed from 28 Feb 2018 to 1 Aug 2018.
- 01 Nov 2017 According to a PhaseBio Pharmaceuticals media release, first patient has been dosed.